ActiTide-AH3 / Acetyl Hexapeptide-8

Short Description:

ActiTide-AH3 is a hexapeptide fragment that mimics the structural domain of the SNAP-25 protein. It competes with SNAP-25, inhibiting the formation of the SNARE complex with syntaxin and VAMP. This blockade prevents membrane fusion and the subsequent release of neurotransmitters. As an instant wrinkle-reducing ingredient, ActiTide-AH3 effectively attenuates dynamic wrinkles caused by localized muscle contraction and helps reduce the number and depth of expression lines. Furthermore, it is mild, non-toxic, and suitable for all skin types. ActiTide-AH3 is widely used in beauty and skincare products, including anti-wrinkle serums, face creams, eye creams, base makeup, and masks, offering comprehensive anti-aging benefits.


Product Detail

Product Tags

Brand name ActiTide-AH3
CAS No. 616204-22-9
INCI Name Acetyl Hexapeptide-8
Application Lotion, Serums, Mask, Facial cleanser
Package 100g/bottle, 1kg/bag
Appearance White to off-white powder
Solubility Water soluble
Function Peptide series
Shelf life 2 years
Storage Store the container tightly closed in a cool, dry place at 2 - 8°C.
Dosage 0.005-0.05%

Application

Research into fundamental anti-wrinkle mechanisms led to the discovery of ActiTide-AH3, an innovative hexapeptide developed through a scientific approach from rational design to GMP production, with positive results.

ActiTide-AH3 delivers wrinkle-reducing efficacy comparable to Botulinum Toxin Type A, while avoiding injection risks and offering greater cost-effectiveness.

Cosmetic Benefits:
ActiTide-AH3 reduces wrinkle depth caused by facial muscle contraction, with pronounced effects on forehead and periocular wrinkles.

Mechanism of Action:
Muscle contraction occurs upon neurotransmitter release from synaptic vesicles. The SNARE complex – a ternary assembly of VAMP, Syntaxin, and SNAP-25 proteins – is essential for vesicle docking and neurotransmitter exocytosis (A. Ferrer Montiel et al., JBC 1997, 272:2634-2638). This complex acts as a cellular hook, capturing vesicles and driving membrane fusion.

As a structural mimetic of the SNAP-25 N-terminus, ActiTide-AH3 competes with SNAP-25 for incorporation into the SNARE complex, modulating its assembly. Destabilization of the SNARE complex impairs vesicle docking and subsequent neurotransmitter release, leading to reduced muscle contraction and prevention of wrinkle and fine line formation.

ActiTide-AH3 is a safer, more economical, and gentler alternative to Botulinum Toxin Type A. It topically targets the same wrinkle-formation pathway but operates via a distinct mechanism.


  • Previous:
  • Next: